Fujing Ge

Zhejiang Province Key Laboratory Of Anti Cancer Drug Research
Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Deubiquitinating enzyme JOSD2 modulates cGAS to facilitate immune evasion in colorectal cancer.

Deubiquitinating enzyme JOSD2 modulates cGAS to facilitate immune evasion in colorectal cancer.

Journal: Oncoimmunology

Published: December 06, 2025

Targeting VCP enhances colorectal cancer therapy through STING stabilization.

Targeting VCP enhances colorectal cancer therapy through STING stabilization.

Journal: Journal for immunotherapy of cancer

Published: November 02, 2025

IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC.

IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC.

Journal: Cell reports

Published: January 08, 2025

JOSD2 promotes breast cancer metastasis by deubiquitinating and stabilizing SMAD4.

JOSD2 promotes breast cancer metastasis by deubiquitinating and stabilizing SMAD4.

Journal: Biochemical pharmacology

Published: September 30, 2024

UniMap: Type-Level Integration Enhances Biological Preservation and Interpretability in Single-Cell Annotation.

UniMap: Type-Level Integration Enhances Biological Preservation and Interpretability in Single-Cell Annotation.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: September 04, 2024

Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer.

Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer.

Journal: Nature communications

Published: July 30, 2024

Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair.

Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair.

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Published: October 30, 2023

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Published: October 30, 2023

Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis.

Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: May 08, 2023

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.

Journal: Signal transduction and targeted therapy

Published: January 05, 2023

The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma.

The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma.

Journal: Expert opinion on therapeutic targets

Published: October 15, 2022

Deubiquitinating enzymes: Promising targets for drug resistance.

Deubiquitinating enzymes: Promising targets for drug resistance.

Journal: Drug discovery today

Published: February 03, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026